Neurorestoration after traumatic brain injury through angiotensin II receptor blockage

Brain

Volumn 138, Issue 11, 2015, Pages 3299-3315

  Villapol, Sonia ^a,b   Balarezo, María G ^a   Affram, Kwame ^a   Saavedra, Juan M ^b   Symes, Aviva J ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

apoptosis; candesartan; inflammation; recovery; telmisartan

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; BLOOD PRESSURE MEASUREMENT; BRAIN BLOOD FLOW; CELL DAMAGE; COGNITION; COGNITIVE DEFECT; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; INFLAMMATION; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CIRCULATION; BRAIN INJURY; DRUG EFFECTS; GENETICS; GLIOSIS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MICROGLIA; NERVE CELL; PATHOLOGY; SIGNAL TRANSDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BENZAMIDES; BENZIMIDAZOLES; BENZOATES; BRAIN INJURIES; CEREBROVASCULAR CIRCULATION; GLIOSIS; INFLAMMATION; MICE; MICE, KNOCKOUT; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; PPAR GAMMA; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; TETRAZOLES;

EID: 84937902241     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv172     Document Type: Article

References (80)

1. Alhusban A, Kozak A, Ergul A, Fagan SC. AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Ther 2013; 344: 348-59.
2. Andriessen TM, Jacobs B, Vos PE. Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J Cell Mol Med 2010; 14: 2381-92.
3. Armando I, Terron JA, Falcon-Neri A, Takeshi I, Hauser W, Inagami T, et al. Increased angiotensin II AT(1) receptor expression in paraventricular nucleus and hypothalamic-pituitary-adrenal axis stimulation in AT(2) receptor gene disrupted mice. Neuroendocrinology 2002; 76: 137-47.
4. Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT(1) receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011; 36: 857-70.
5. Bennai F, Morsing P, Paliege A, Ketteler M, Mayer B, Tapp R, et al. Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats. J Am Soc Nephrol 1999; 10 (Suppl 11): S104-15.
6. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
7. Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006; 34(Pt 6): 1341-6.
8. Cabaleiro T, Roman M, Ochoa D, Talegon M, Prieto-Perez R, Wojnicz A, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 2013; 41: 224-9.
9. Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag 2011; 7: 749-59.
10. Deppe S, Boger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 2010; 6: 863-71.
11. Diaz-Arrastia R, Kochanek PM, Bergold P, Kenney K, Marx CE, Grimes CJ, et al. Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup. J Neurotrauma 2014; 31: 135-58.
12. Fleegal-DeMotta MA, Doghu S, Banks WA. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab 2009; 29: 640-7.
13. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hyperten 2003; 17: 781-5.
14. Fukui Y, Yamashita T, Kurata T, Sato K, Lukic V, Hishikawa N, et al. Protective effect of telmisartan against progressive oxidative brain damage and synuclein phosphorylation in stroke-resistant spontaneously hypertensive rats. J Stroke Cerebrovasc Dis 2014; 23: 1545-53.
15. Garrido-Gil P, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J Neuroinflammation 2012; 9: 38.
16. Gillespie W, Tyagi N, Tyagi SC. Role of PPARgamma, a nuclear hormone receptor in neuroprotection. Indian J Biochem Biophys 2011; 48: 73-81.
17. Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002; 41: 7-17.
18. Guan W, Somanath PR, Kozak A, Goc A, El-Remessy AB, Ergul A, et al. Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PloS One 2011; 6: e24551.
19. Hajjar I, Brown L, Mack WJ, Chui H. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012; 69: 1632-8.
20. Hajjar I, Hart M, Chen YL, Mack W, Novak V, Chiu H, et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc 2013; 61: 194-201.
21. Hamai M, Iwai M, Ide A, Tomochika H, Tomono Y, Mogi M, et al. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 2006; 51: 822-8.
22. Hsu CY, Huang CC, Chan WL, Huang PH, Chiang CH, Chen TJ, et al. Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population - A nationwide cohort study. Circ J 2013; 77: 405-10.
23. Ishrat T, Pillai B, Soliman S, Fouda AY, Kozak A, Johnson MH, et al. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. Mol Neurobiol 2015; 51: 1542-53.
24. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33: 2297-303.
25. Johren O, Saavedra JM. Expression of AT1A and AT1B angiotensin II receptor messenger RNA in forebrain of 2-wk-old rats. Am J Physiol 1996; 271(1 Pt 1): E104-12.
26. Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodriguez V, Desland F, et al. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology 2014; 81: 134-41.
27. Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH, et al. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007; 322: 1051-8.
28. Justin A, Sathishkumar M, Sudheer A, Shanthakumari S, Ramanathan M. Non-hypotensive dose of telmisartan and nimodipine produced synergistic neuroprotective effect in cerebral ischemic model by attenuating brain cytokine levels. Pharmacol Biochem Behav 2014; 122: 61-73.
29. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008; 13: 1813-26.
30. Kasahara Y, Taguchi A, Uno H, Nakano A, Nakagomi T, Hirose H, et al. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res 2010; 1340: 70-80.
31. Kozak A, Ergul A, El-Remessy AB, Johnson MH, Machado LS, Elewa HF, et al. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke 2009; 40: 1870-6.
32. Kozak W, Kozak A, Johnson MH, Elewa HF, Fagan SC. Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J Pharmacol Exp Ther 2008; 326: 773-82.
33. Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav Immun 2012; 26: 1191-201.
34. Li JJ, Lu J, Kaur C, Sivakumar V, Wu CY, Ling EA. Expression of angiotensin II and its receptors in the normal and hypoxic amoeboid microglial cells and murine BV-2 cells. Neuroscience 2009; 158: 1488-99.
35. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
36. Liu H, Kitazato KT, Uno M, Yagi K, Kanematsu Y, Tamura T, et al. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies. J Hypertens 2008; 26: 1435-45.
37. Lu GC, Cheng JW, Zhu KM, Ma XJ, Shen FM, Su DF. A systematic review of angiotensin receptor blockers in preventing stroke. Stroke 2009; 40: 3876-8.
38. McConeghy KW, Hatton J, Hughes L, Cook AM. A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury. CNS Drugs 2012; 26: 613-36.
39. Meredith PA, Murray LS, McMurray JJ. A putative placebo comparison of the SCOPE and LIFE trials. J Renin Angiotensin Aldosterone Syst 2004; 5: 59-63.
40. Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65: 809-48.
41. Mitchell K, Shah JP, Tsytsikova LV, Campbell AM, Affram K, Symes AJ. LPS antagonism of TGF-beta signaling results in prolonged survival and activation of rat primary microglia. J Neurochem 2014; 129: 155-68.
42. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, et al. Telmisartan prevented cognitive decline partly due to PPARgamma activation. Biochem Biophys Res Commun 2008; 375: 446-9.
43. Nishimura Y, Ito T, Hoe K, Saavedra JM. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 2000; 871: 29-38.
44. Noda A, Fushiki H, Murakami Y, Sasaki H, Miyoshi S, Kakuta H, et al. Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques. Nucl Med Biol 2012; 39: 1232-5.
45. Ohshima K, Mogi M, Horiuchi M. Therapeutic approach for neuronal disease by regulating renin-angiotensin system. Curr Hypertens Rev 2013; 9: 99-107.
46. Omura-Matsuoka E, Yagita Y, Sasaki T, Terasaki Y, Oyama N, Sugiyama Y, et al. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. Hypertens Res 2009; 32: 548-53.
47. Ozacmak VH, Sayan H, Cetin A, Akyildiz-Igdem A. AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion. Neurochem Res 2007; 32: 1314-21.
48. Pelisch N, Hosomi N, Mori H, Masaki T, Nishiyama A. RAS inhibition attenuates cognitive impairment by reducing blood-brain barrier permeability in hypertensive subjects. Curr Hypertens Rev 2013; 9: 93-8.
49. Rodriguez-Perez AI, Borrajo A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation. Glia 2015; 63: 466-82.
50. Saavedra JM. Brain and pituitary angiotensin. Endocr Rev 1992; 13: 329-80.
51. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25: 485-512.
52. Saavedra JM. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond) 2012; 123: 567-90.
53. Saavedra JM, Benicky J, Zhou J. Angiotensin II: multitasking in the brain. J Hypertens Suppl 2006; 24: S131-7.
54. Sasamura H, Hein L, Krieger JE, Pratt RE, Kobilka BK, Dzau VJ. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Commun 1992; 185: 253-9.
55. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-7.
56. Soliman S, Ishrat T, Pillai A, Somanath PR, Ergul A, El-Remessy AB, et al. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B. J Pharmacol Exp Ther 2014; 349: 444-57.
57. Stangier J, Su CA, Schondorfer G, Roth W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000; 40(12 Pt 1): 1355-64.
58. Steckelings UM, Unger T. Angiotensin II type 2 receptor agonists-where should they be applied? Expert Opin Investig Drugs 2012; 21: 763-6.
59. Sumners C, Horiuchi M, Widdop RE, McCarthy C, Unger T, Steckelings UM. Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol 2013; 40: 580-8.
60. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11: 21-30.
61. Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006; 24: S115-21.
62. Timaru-Kast R, Wyschkon S, Luh C, Schaible EV, Lehmann F, Merk P, et al. Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit Care Med 2012; 40: 935-44.
63. Tota S, Kamat PK, Awasthi H, Singh N, Raghubir R, Nath C, et al. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 2009; 199: 235-40.
64. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009; 54: 782-7.
65. Umschweif G, Liraz-Zaltsman S, Shabashov D, Alexandrovich A, Trembovler V, Horowitz M, et al. Angiotensin receptor type 2 activation induces neuroprotection and neurogenesis after traumatic brain injury. Neurotherapeutics 2014; 11: 665-78.
66. Villapol S, Bonnin P, Fau S, Baud O, Renolleau S, Charriaut-Marlangue C. Unilateral blood flow decrease induces bilateral and symmetric responses in the immature brain. Am J Pathol 2009; 175: 2111-20.
67. Villapol S, Byrnes KR, Symes AJ. Temporal dynamics of cerebral blood flow, cortical damage, apoptosis, astrocyte-vasculature interaction and astrogliosis in the pericontusional region after traumatic brain injury. Front Neurol 2014; 5: 82.
68. Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 2015; 28; 289-99.
69. Villapol S, Yaszemski AK, Logan TT, Sanchez-Lemus E, Saavedra JM, Symes AJ. Candesartan, an angiotensin II AT(1)-receptor blocker and PPAR-gamma agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology 2012; 37: 2817-29.
70. Villela D, Leonhardt J, Patel N, Joseph J, Kirsch S, Hallberg A, et al. Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci (Lond) 2015; 128: 227-34.
71. Wang J, Pang T, Hafko R, Benicky J, Sanchez-Lemus E, Saavedra JM. Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARgamma activation. Neuropharmacology 2014; 79: 249-61.
72. Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, et al. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med 2014; 371: 2457-66.
73. Wright JW, Harding JW. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev 1994; 18: 21-53.
74. Wright JW, Harding JW. Brain renin-angiotensin - A new look at an old system. Prog Neurobiol 2011; 95: 49-67.
75. Wu CY, Zha H, Xia QQ, Yuan Y, Liang XY, Li JH, et al. Expression of angiotensin II and its receptors in activated microglia in experimentally induced cerebral ischemia in the adult rats. Mol Cell Biochem 2013; 382: 47-58.
76. Yamashita T, Zhai Y, Kurata T, Hishikawa N, Morimoto N, Ohta Y, et al. Strong improvement of apolipoprotein E/low-density lipoprotein receptor signals by telmisartan in poststroke spontaneously hypertensive stroke resistant. J Stroke Cerebrovasc Dis 2014; 23: 2240-9.
77. Zanchetti A, Elmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - A review. Blood Press 2006; 15: 71-9.
78. Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T. Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 2010; 171: 852-8.
79. Zhou J, Pavel J, Macova M, Yu ZX, Imboden H, Ge L, et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006; 37: 1271-6.
80. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006; 552: 112-22.